Figure 2.

Study protocol diagram. Healthy women attended for 2 consecutive menstrual cycles. In each cycle, blood samples were taken on days 3 or 4, 9 or 10, 15 or 16, and 21 or 22 to measure serum reproductive hormone levels, and plasma elinzanetant levels (cycle 2 only). No treatment was given in cycle 1 (baseline). During cycle 2, participants were randomly assigned to receive placebo or elinzanetant 40 mg, 80 mg, or 120 mg (N = 8 per group [9 for the 80-mg dose]) for up to 21 days.